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In 1947 it was shown that during development of the male
fetus a testicular factor distinct from testosterone caused
regression of the Müllerian ducts, which form the anlagen of
the female genital tract (Jost, 1947; Munsterberg and Lovell-
Badge, 1991). This factor was called anti-Müllerian hormone
(AMH) and was subsequently identified as a dimeric glyco-
protein related to transforming growth factor b (TGFb ) (Cate
et al., 1986). Together with inhibins, activins, bone morpho-
genetic proteins (BMPs), and growth and differentiation
factors (GDFs), AMH is part of the TGFb superfamily of
peptide growth and differentiation factors (Massagué, 1990).
Members of this family have a broad range of functions in
mesenchymal–epithelial interactions, cell growth, extracellular
matrix production and tissue remodelling (Massagué and
Chen, 2000). In men, strong AMH expression is found in
Sertoli cells from the moment of testicular differentiation
during fetal development up to puberty, whereas in women
AMH is produced by ovarian granulosa cells from about
week 36 of gestation to menopause (Lee et al., 1996;
Rajpert-De Meyts et al., 1999).
AMH receptors
Members of the TGFb family signal through two related
transmembrane serine–threonine kinase receptors, referred
to as type I and type II receptors. Upon binding of the ligand
to its type II receptor, the type I receptor is recruited to form
a heterotetrameric receptor complex. Activation of the type I
receptor through transphosphorylation by the type II
receptor leads to subsequent downstream signalling via
Smad proteins (for a review, see Massagué and Chen,
2000).
The type II receptor for AMH (AMHRII) was cloned several
years ago (rat: Baarends et al., 1994; rabbit: di Clemente
et al., 1994a). Expression of AMHRII mRNA was found in
the mesenchymal cells surrounding the Müllerian ducts
(Baarends et al., 1994) and, in addition, in fetal and adult
gonads of both sexes. Generation of AMHRII-deficient mice
proved that this type II receptor is essential for AMH
signalling, as demonstrated by the lack of Müllerian duct
regression in AMHRII-deficient male mice (Mishina et al.,
1996). In addition, the relevance of this receptor to AMH
action was further demonstrated by the identification of
mutations in the AMHRII gene of patients with persistent
Müllerian duct syndrome (PMDS) (Imbeaud et al., 1996;
Josso et al., 1997).
More insight into the identity of the AMH type I receptor
has been gained recently. Members of the TGFb family can
use several different type I receptors to exert their effects.
Two distinct sets of type I receptors can be made. Activin
receptor-like kinase 1 (ALK1), ALK4 and ALK5 form the
TGF b –activin group of type I receptors, whereas ALK2,
ALK3 and ALK6 form the BMP group (Nakao et al., 1997;
Massagué and Chen, 2000). It has been shown that 
AMH signals via the type I receptors of the BMP group.
Experiments in vitro and organ culture experiments ex vivo ,
using an anti-sense oligo approach, revealed that ALK2 is
involved in AMH-induced Müllerian duct regression (Visser
et al., 2001). ALK2-deficient mice are embryonically lethal
and therefore do not provide additional information on
ALK2 functioning as an AMH type I receptor. Generation of
ALK3 conditional knockout mice showed that ALK3 might
be involved in AMH signalling during induced Müllerian
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duct regression (for a review, see Teixeira, 2001); however,
the role of ALK6 in AMH signalling is still questionable. 
Studies in vitro showed an AMH-dependent interaction
between AMHRII and ALK6 (Gouedard et al., 2000).
However, antisense ALK6 oligos or mutated ALK6 func-
tioning as a dominant negative type I receptor did not
disrupt AMH signalling (Clarke et al., 2001; Visser et al.,
2001) and male ALK6-deficient mice do not retain their
Müllerian ducts. These observations indicate that ALK6 is,
at least during Müllerian duct regression, not crucial as an
AMH type I receptor (Clarke et al., 2001). Together, these
results indicate that AMH, like BMPs, might signal through
different type I receptors in a tissue- and cell-specific
manner. Further studies are necessary to elucidate which
signal transduction pathway is used by AMH in the ovary.
Expression of AMH and its receptors in the ovary
In contrast to its expression in male mice and rats, AMH is
not expressed in female rodents before birth (Munsterberg
and Lovell-Badge, 1991; Hirobe et al., 1992; Taketo et al.,
1993; J. A. Visser and A. P. N. Themmen, unpublished), and
this lack of expression guarantees a normal differentiation of
the female internal reproductive tract structures. However,
a few days after birth, this sexually dimorphic pattern of
expression of AMH disappears and AMH expression is
easily detected in granulosa cells of growing follicles (Ueno
et al., 1989; Hirobe et al., 1992; Durlinger et al., 2002). In
mice and rats, AMH displays a specific window of
expression. It is first detected in the granulosa cells of early
primary follicles (Munsterberg and Lovell-Badge, 1991;
Taketo et al., 1993; Durlinger et al., 2002). Expression is
highest in granulosa cells of preantral and small antral
follicles (Fig. 1a). Within these follicles, AMH expression is
not always evenly distributed, as in some follicles
expression is highest in the granulosa cells immediately
surrounding the antrum and around the oocyte (Fig. 1b)
(Ueno et al., 1989; Hirobe et al., 1992, 1994; Baarends et
al., 1995; Durlinger et al., 2002). This gradient of AMH
expression within a follicle may reflect functional
differences between the granulosa cells surrounding the
oocyte and the more peripheral granulosa cells, such as
differences in proliferation capacity and steroidogenic
activity (Baarends et al., 1995). These functional differences
may arise under the influence of factors produced by the
oocyte, as has been shown for oocyte factor GDF9 (Elvin
et al., 1999a). Some studies report that, in rats, AMH
expression can be found until the preovulatory stage (Ueno
et al., 1989; Hirobe et al., 1994), whereas other studies
report that AMH is not detected from the small antral follicle
stage onward (Hirobe et al., 1992; Baarends et al., 1995).
Follicles showing signs of atresia also have decreased or no
AMH expression, and expression is completely lost in
corpora lutea (Fig. 1d). AMH is never found in primordial
follicles, theca cells, oocytes or the interstitium (Fig. 1c,d;
Ueno et al., 1989; Hirobe et al., 1992, 1994; Baarends et al.,
1995; Durlinger et al., 2002). In rats, no differences occur
during the oestrous cycle in the pattern of expression in
follicles of the same class, although some heterogeneity has
been observed in AMH mRNA expression in preantral and
small antral follicles at oestrus and dioestrus (Hirobe et al.,
1994; Baarends et al., 1995).
In contrast to AMH, the AMH type II receptor does not
show a sexually dimorphic pattern of expression. Expression
is found in Müllerian duct mesenchymal cells and gonads of
both sexes (Baarends et al., 1994; di Clemente et al.,
1994b). In the postnatal ovary of mice and rats, AMHRII
expression colocalizes with AMH in the granulosa cells,
showing a similar expression window (Baarends et al.,
1995; A. L. L. Durlinger and A. P. N. Themmen, unpublished).
In addition, the theca cells of preantral and small antral
follicles in rat ovaries express AMHRII (Ingraham et al.,
2000). 
The candidate AMH type I receptor ALK2 is also
expressed in fetal and adult mouse ovaries (Visser et al.,
2001), although its exact cellular and spatial pattern of
expression remains to be determined; this is also true for
expression of ALK3 mRNA in the ovaries of mouse fetuses
(Dewulf et al., 1995). ALK6 is not expressed in the ovaries of
mouse fetuses (Visser et al., 2001), but in the adult ovary,
ALK6 is expressed in oocytes of small antral follicles, and in
both the oocytes and granulosa cells of large antral follicles
(Yi et al., 2001), and, therefore, it does not colocalize with
ovarian AMHRII. More detailed expression studies are
needed to establish the exact localization of all AMH type I
receptors.
AMH action in the ovary
The specific patterns of expression of AMH and AMHRII in
the ovary indicate that AMH may play a role during follicle
development and function. The first report on AMH action
in the ovary showed that bovine AMH inhibited meiotic
maturation of both denuded and cumulus-enclosed rat
oocytes in vitro (Takahashi et al., 1986). However, Tsafriri
et al. (1988) were not able to reproduce these results and no
subsequent reports have been published on the effects of
AMH on oocyte maturation. On the basis of the pattern of
expression of the receptors described in this review, it is
much more likely that AMH exerts its effect on ovarian
follicles via the granulosa and theca cells, and not via the
oocyte.
The generation of transgenic mice over-expressing AMH
revealed that the presence of AMH during the fetal period is
detrimental for ovarian development (Behringer et al.,
1990). Female transgenic mice are infertile and most have a
blind-ending vagina due to the absence of a uterus and
oviducts. Although the ovaries are present at birth, in most
animals the ovaries are devoid of germ cells and develop
cord-like structures within 2 weeks after birth. In adult
females, the ovaries have degenerated. Ovarian develop-
ment appeared unaffected only in mice with the lowest
serum AMH concentrations. Thus, in mice, the presence of
AMH during the fetal period clearly has an impact on
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ovarian and female germ cell development. However,
inferences cannot be drawn from this mouse model with
respect to a possible role of AMH in postnatal follicle
development and function. 
AMH inhibits initiation of primordial follicle growth
More insight into the role of AMH in the ovary was
obtained from our studies of AMH-deficient (AMHKO) mice.
Male AMHKO mice retain their Müllerian duct derivatives
and in some male mice Leydig cell hyperplasia is also
observed. The AMHKO males are fertile, although their
fertility is impaired for anatomical reasons. In female
AMHKO mice, the lack of AMH does not affect fertility and
initially no obvious ovarian abnormalities were observed
(Behringer et al., 1994). 
Despite this lack of an ovarian phenotype in AMHKO
females, it is possible that AMH might be involved in subtle
and long-term aspects of control of follicle development
(Durlinger et al., 1999). This contention was based on the
prominent and specific patterns of expression of AMH and
AMHRII in the postnatal ovary and on the marked changes
in expression of AMH and AMHRII mRNA during the
oestrous cycle in rats (Baarends et al., 1995). A study of 
the entire follicle population in AMHKO females was
performed to test this hypothesis (Durlinger et al., 1999) and
revealed that, in the absence of AMH, ovaries are depleted
of their primordial follicles earlier than they are in control
mice, as ovaries of adult and aged AMHKO females contain
fewer primordial follicles than do ovaries of their wild-type
littermates (Fig. 2). This decrease is caused by increased
recruitment of primordial follicles in AMHKO females, as
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Fig. 1. Immunohistochemical localization of anti-Müllerian hormone (AMH) in a 30-day-old and a 4-month-old C57Bl/6J mouse ovary. (a)
Section of an ovary of a 30-day-old mouse. AMH is found in granulosa cells from early primary follicles (P) and is highly expressed in
granulosa cells of larger preantral (PA) and small antral (SA) follicles. (b) Section of an ovary of a 30-day-old mouse. AMH expression is
decreased in antral (A) and atretic (At) follicles. The granulosa cells surrounding the antrum or the oocyte are the last cells to lose AMH
expression. (c) Section of a 30-day-old mouse ovary. AMH expression is not present in primordial follicles (pr), oocytes (O) or theca cells
(T). (d) Section of a 4-month-old mouse ovary. AMH expression is not found in the corpus luteum (CL) or the interstitium (I). Scale bars
represent (a,c) 20 m m and (b,d) 40 m m. (Adapted from Durlinger, 2000.)
more preantral and small antral follicles (together referred to
as small follicles) are found in prepubertal and adult
AMHKO mice (Fig. 2). This increase in the number of small
follicles is reflected by a twofold increase in total ovarian
mass of adult AMHKO females relative to wild-type controls
(Durlinger et al., 1999). Mice heterozygous for the amh
mutation have an intermediate phenotype (not shown). This
AMH gene dose-dependency indicates that ovarian AMH
production or secretion may not be under stringent
feedback control, but instead depends on the intrinsic
activity of the gene itself.
The above-mentioned results indicate that AMH may be
able to inhibit the initiation of follicle growth, a process also
known as follicle activation or initial recruitment (McGee
and Hsueh, 2000). Durlinger et al. (2002) confirmed this
conclusion by a study in which neonatal mouse ovaries
were cultured in vitro for 2 or 4 days in the absence or
presence of AMH. Ovaries of 2-day-old mice contain
predominantly primordial follicles and some naked
oocytes, but no growing follicles and, therefore, they
provide an excellent model to investigate the influence of
AMH on the recruitment of primordial follicles. AMH
caused a 40–50% decrease in the number of growing
follicles after 2 and 4 days of culture (Table 1). Consistent
with these findings, a decreased expression of inhibin 
a -subunit mRNA was found in AMH-treated ovaries
compared with control ovaries. In contrast, expression of
AMHRII and the oocyte markers GDF9 and zona pellucida
protein 3 (ZP3) were not influenced by AMH. These results
show that AMH is able to inhibit the initiation of primordial
follicle growth and therefore functions as an inhibitory
growth factor in the ovary during the early stages of
folliculogenesis. This inhibitory effect is probably the result
of a paracrine, (pre)granulosa cell-derived effect of AMH on
the primordial follicle. An RNase protection assay showed
that expression of AMHRII mRNA, which is essential for an
effect of AMH, is present in ovaries of 2-day-old mice
(Durlinger et al., 2002). In addition, in situ hybridization
studies demonstrated ovary-specific AMHRII expression in
neonatal ovaries, although exact localization of the AMHRII
expression to the pregranulosa cells was not possible
because the radioactive AMHRII probe is best visualized
using a microscope with dark field, making it difficult to
discern specific structures or types of cell in neonatal
ovaries (J. A. Visser, A. L. L. Durlinger and A. P. N. Themmen,
unpublished).
The inhibitory effect of AMH on primordial follicle
recruitment is consistent with our previous observation that
the absence of, or reduced, AMH production in females
results in an earlier depletion of the stock of primordial
follicles. Therefore, the formation of preovulatory follicles
would be expected to cease at a younger age in AMHKO
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Fig. 2. Follicle population in prepubertal, adult and aged wild-type (h) and anti-Müllerian hormone
knockout (AMHKO; j) female mice. Mice were killed at oestrus. Follicles were counted in both ovaries.
Data represent the mean number of follicles per two ovaries 6 SEM (4–5 animals per genotype). The
number of primordial follicles was significantly lower in adult (4 months of age) and aged (13 months of
age) AMHKO female mice compared with the number in their wild-type littermates. Significantly more
growing follicles were detected in prepubertal (25 days of age) and adult AMHKO female mice, whereas
in aged AMHKO female mice the number of growing follicles was significantly lower. Asterisks indicate
a significant difference (P < 0.05). (Adapted from Durlinger et al., 1999.) 
females than in wild-type females, as the size of the
primordial follicle pool is positively correlated with the
duration of the reproductive lifespan of the female. This
contention is clearly supported by, for example, the Bax-
deficient female mouse model. Bax is involved in the
execution of apoptosis, or programmed cell death, in many
types of cell. In Bax-deficient females, the stock of
primordial follicles shrinks much more slowly than it does
in wild-type females, resulting in sustained ovarian function
in aged Bax-deficient mice (20–22 months) (Perez et al.,
1999).
A premature exhaustion of the follicle pool predicts an
earlier cessation of ovulation in ageing animals. Indeed,
when the presence of corpora lutea was used as an
indication of ovulatory cycles, it was found that 56% of
AMHKO females compared with only 18% of the aged
wild-type females had stopped ovulating at 16–17 months
of age (Durlinger, 2000). 
Studies on the use of AMH as a marker for ovarian ageing
in women have recently started. A study in young normo-
ovulatory women showed that serum concentrations of
AMH decrease over time and with advancing age before
changes occur in other currently known ageing-related
variables, such as serum concentrations of FSH and inhibin
B, and the number of antral follicles (de Vet et al., 2002).
Furthermore, a strong correlation was found between serum
concentrations of AMH and the number of antral follicles,
meaning that low serum AMH concentrations coincide 
with low numbers of antral follicles. A similar correlation
was found on day 3 of the menstrual cycle in women
undergoing in vitro fertilization (IVF) treatment (I. van Rooij,
A. P. N. Themmen and E. R. te Velde, unpublished). As 
the age-related decrease in number of antral follicles
corresponds to the age-related decrease in the number of
primordial follicles (Scheffer et al., 1999), it can be
postulated that serum AMH concentration is a good
indication of the size of the ovarian follicle pool and, thus,
of ovarian ageing. Support for the use of serum AMH
concentration as a marker for ovarian response in women
undergoing controlled ovarian stimulation for IVF is
provided by the demonstration of an association between
higher serum AMH concentration and a larger number of
retrieved oocytes (I. van Rooij, A. P. N. Themmen and E. R.
te Velde, unpublished). A similar observation has been
made in another study in women undergoing IVF treatment
(Seifer et al., 2002).
AMH is not the only regulator of initial recruitment. In
addition to the inhibitory effect of AMH, initiation of follicle
growth can also be positively influenced by stem cell factor
(SCF; Parrott and Skinner, 1999), GDF9 (Vitt et al., 2000),
basic fibroblast growth factor (bFGF) (Nilsson et al., 2001)
and nerve growth factor (NGF) (Dissen et al., 2001). It
would be interesting to study the possible functional
interactions of these different factors in initial recruitment.
Indications for such an interaction have already been
detected for SCF and GDF9. Expression of SCF mRNA is
greatly increased in mice lacking GDF9 (GDF9KO), indicating
that GDF9 may be one of the oocyte-secreted factors that
negatively regulates SCF expression (Elvin et al., 1999b),
although it seems more likely that this difference in
expression of SCF mRNA in intact ovaries is caused by the
radical change in composition of the follicle population in
GDF9KO mice (Dong et al., 1996).
AMH inhibits FSH-stimulated follicle growth
Studies of female AMHKO mice have revealed that
AMH, in addition to its role in primordial follicle recruitment,
plays a role in fine-tuning the sensitivity of growing follicles
to FSH. Despite a lower serum FSH concentration, ovaries
of 4-month-old AMHKO mice contain more growing
follicles than do ovaries of their wild-type littermates
(Durlinger et al., 1999), indicating that AMH may inhibit
FSH-induced follicle growth. This hypothesis was confirmed
by culture of mouse preantral follicles in vitro. Addition of
AMH to the culture inhibited FSH-induced follicle growth
in a time-dependent manner, as follicles cultured in the
presence of AMH (at days 4 and 5 of culture) had a
significantly smaller diameter. This AMH-induced inhibition
in follicle growth was mainly the result of reduced granulosa
cell proliferation, compared with FSH stimulation alone
(Durlinger et al., 2001). In contrast, McGee et al. (2001)
described a stimulatory effect of AMH on FSH-induced
growth of rat follicles. Although both the above studies used
preantral follicles, species differences and absence or
presence of serum (that is, other growth factors) in the
culture medium may account for the opposing results (E. A.
McGee, personal communication). The results of two in
vitro studies in which exogenous AMH reduced expression
of aromatase mRNA and decreased the number of LH re-
ceptors in cultured granulosa cells are in agreement with an
inhibitory effect of AMH on follicle growth (di Clemente et al.,
1994a). In addition, AMH opposes EGF-induced pro-
liferation of cultured granulosa-luteal cells (Kim et al., 1992).
The inhibitory effect of AMH on FSH-stimulated follicle
growth was also confirmed in an in vivo model in which
follicle growth in the presence of high or low serum FSH
concentrations was compared between AMHKO females
and their wild-type littermates (Durlinger et al., 2001). This
study showed that, in the presence of low serum FSH
concentrations, more growing follicles were found in
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Table 1. Inhibitory effect of anti-Müllerian hormone (AMH) on the
number of growing follicles in an in vitro 2-day-old mouse ovarian
culture
Day of culture Control + AMH
2 81 (100%) (n = 9) 50 (59%)* (n = 9)
4 153 (100%) (n =11) 97 (66%)* (n = 11)
n = number of ovaries examined.
%: the number of growing follicles of the control was set at 100%.
*Indicates a significant difference from control (no AMH; P < 0.05).
AMHKO females, whereas in the presence of high serum
FSH concentrations, stimulation of follicle growth was more
pronounced in AMHKO females than in wild-type females,
both in terms of numbers and developmental stage (Fig. 3).
These findings also indicate that, in the absence of AMH,
follicles are more responsive to FSH.
This modulation of responsiveness to FSH by AMH could
be very important during the process of cyclic recruitment.
During cyclic recruitment in mice and rats, a group of
follicles is recruited from the pool of large preantral and
small antral follicles to continue growth to the preovulatory
stage. Cyclic recruitment (McGee and Hsueh, 2000) takes
place at oestrus, as a result of the secondary surge of FSH.
This FSH peak is important for the number of follicles 
that are recruited (Hirshfield and De Paolo, 1981; van
Cappellen et al., 1993). It is thought that, depending on the
stage of development, each follicle requires a certain
concentration of FSH to continue growth; that is, each
follicle displays its own FSH threshold concentration and
this threshold concentration has to be exceeded to ensure
growth to the preovulatory stage. This concept of an FSH
threshold was developed after studies in humans (Brown,
1978). AMH may be one of the factors involved in
determining the responsiveness of the follicle to FSH during
cyclic recruitment. A role for AMH in cyclic recruitment is
supported by the differential pattern of expression of AMH
observed at oestrus in non-atretic large preantral and small
antral follicles (Baarends et al., 1995). Although these follicles
are morphologically indistinguishable, some follicles show
high AMH expression whereas others have a much lower
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Fig. 3. Number of growing follicles in the presence of (a) low or (b)
high serum FSH concentrations in prepubertal wild-type (h) and
anti-Müllerian hormone knockout (AMHKO; j) female mice. Data
represent the mean number of follicles per two ovaries 6 SEM
(n = 6 animals per group). In the presence of both low and high
serum FSH concentrations, more growing follicles are found in
AMHKO females compared with wild-type females. Asterisks indi-
cate a significant difference from wild-type females within the same
treatment group (P < 0.05). (Adapted from Durlinger et al., 2001.)
(a)
(b)
Fig. 4. Follicle population in adult wild-type (h), anti-Müllerian
hormone knockout (AMHKO; j), FSHb knockout (FSH b KO; 9),
and FSH b and AMH knockout (FAKO; 8) female mice. Wild-type
and AMHKO females were killed at oestrus. Follicles were counted
in one ovary. Data represent the mean number of follicles per
ovary 6 SEM (n = 4 animals per genotype). There is no significant
difference for both the number of (a) primordial and (b) growing
follicles between wild-type and FSHb KO females. In both AMHKO
and FAKO females, the number of primordial follicles is lower,
whereas the number of growing follicles is higher compared with
wild-type females. aIndicates a significant difference compared
with the wild type; bindicates a significant difference from AMHKO
mice; cindicates a significant difference from FSHb KO mice; and
dindicates a significant difference from FAKO females (P < 0.05).
(Adapted from Durlinger et al., 2001.)
AMH expression. Low AMH expression would correlate
with increased sensitivity to FSH, allowing these follicles to
be selected for continued growth and ovulation in the next
oestrous cycle. Indeed, in a preliminary study, using 5-
bromodeoxyuridine (BrDU) as a cell proliferation marker, in
rats, more proliferating granulosa cells were found in
follicles that expressed less AMH, and vice versa (Durlinger,
2000).
The inhibitory action of AMH on growth stimulation 
by FSH can also be relevant for small preantral follicles.
Although these follicles do not depend on FSH for their
growth (Halpin and Charlton, 1988; Kumar et al., 1997),
they are sensitive to FSH (van Cappellen et al., 1989;
McGee et al., 1997). Therefore, complete loss of FSH
production in mice would be expected to change preantral
follicle growth. However, a study of the follicle population
of 4-month-old FSHb -deficient (FSHb KO) and wild-type
female mice revealed that the absence of FSH had no
impact on the number of primordial and preantral–small
antral follicles (Fig. 4) (Durlinger et al., 2001). The same
study revealed that, in female mice lacking both fsh b and
amh expression (FAKO), the ovarian phenotype caused 
by AMH-deficiency is even more pronounced (Fig. 4),
indicating that AMH may be a much more dominant
regulator of early follicle growth than FSH. 
Thus, in addition to factors that stimulate preantral
follicle growth, such as FSH (Halpin and Charlton, 1988;
van Cappellen et al., 1989), stem cell factor (SCF; Parrott
and Skinner, 1997) and GDF9 (Hayashi et al., 1999),
inhibitory factors such as AMH are important in making
preantral follicle growth a well-balanced process.
AMH and cancer in women
As AMH expression is restricted to ovarian granulosa
cells in women, AMH may prove a useful serum marker of
granulosa cell tumours (GTCs). Indeed, several studies
showed an increased serum AMH concentration in women
with both primary and recurrent GTCs (Gustafson et al.,
1992; Rey et al., 1996; Silverman and Gitelman, 1996; Lane
et al., 1999; Rey et al., 2000). An ultrasensitive enzyme-
linked immunosorbent assay (ELISA) has been developed
using immunopurified monoclonal AMH antibodies to
enhance the availability and sensitivity of serum AMH
determination (Long et al., 2000), enabling researchers to
detect the recurrences of GTCs at an early, preclinical stage. 
AMH is not only a useful GCT marker but may also be
applicable as a chemotherapeutic agent for ovarian epithelial
tumours, as AMH causes regression of the Müllerian ducts,
which arise from a common embryological precursor with
the surface epithelium of the ovary, from which epithelial
ovarian tumours originate (Scully, 1995). Several studies by
P. Donahoe and co-workers have shown that AMH inhibits
proliferation of cells derived from non-ovarian tumours
(Fuller et al., 1985; Chin et al., 1991; Parry et al., 1992).
More recent studies have demonstrated that growth of
ovarian tumours of epithelial origin is also inhibited by
AMH (Masiakos et al., 1999; Ha et al., 2000), causing the
cells to accumulate in the G1 phase of the cell cycle and
subsequently to undergo apoptosis (Ha et al., 2000). The
inhibitory effect of AMH on the growth of epithelial ovarian
tumour cells is probably mediated via AMHRII, as these
tumour cells express AMHRII (Masiakos et al., 1999). AMH
may also be able to act as a therapeutic agent for ovarian
cancer in vivo, as was demonstrated in a study in which
growth of human ovarian cancer cell line (IGROV-1)
implanted under the renal capsule of the kidney of immuno-
deficient mice was inhibited in animals ‘treated’ with an
AMH-expressing cell line (Stephen et al., 2001).
Conclusion
In conclusion, several studies on the function of AMH in the
postnatal ovary indicate that AMH has at least two functions
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Fig. 5. Action of anti-Müllerian hormone (AMH) in the postnatal ovary. AMH produced by preantral
and small antral follicles in the postnatal ovary has two sites of action in the postnatal ovary. (1) It
inhibits initial recruitment and (2) it inhibits the stimulatory effect of FSH on the growth of preantral and
small antral follicles.
during follicular development (Fig. 5). First, AMH plays an
inhibitory role during initial recruitment, when resting
primordial follicles are initiated to grow, and second, it 
may modify preantral and small antral follicle growth by
decreasing the FSH-responsiveness of the follicle. The
second effect may be important during cyclic recruitment,
when certain large preantral and small antral follicles are
recruited to grow on to the preovulatory follicle stage. 
Furthermore, in women, there are indications that AMH
can be used as a marker for ovarian ageing and as a marker
for ovarian response in women undergoing IVF treatment.
AMH has also proved to be a marker for granulosa cell
tumours and has potential to be used as a therapeutic agent
for ovarian epithelial tumours.
References
Key references are identified by asterisks.
Baarends WM, van Helmond MJ, Post M et al. (1994) A novel member 
of the transmembrane serine/threonine kinase receptor family is
specifically expressed in the gonads and in mesenchymal cells adjacent
to the Müllerian duct Development 120 189–197
Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC,
Themmen AP and Grootegoed JA (1995) Anti-Müllerian hormone and
anti-Müllerian hormone type II receptor messenger ribonucleic acid
expression in rat ovaries during postnatal development, the estrous
cycle and gonadotropin-induced follicle growth Endocrinology 136
4951–4962
Behringer RR, Cate RL, Froelick GJ, Palmiter RD and Brinster RL (1990)
Abnormal sexual development in transgenic mice chronically expressing
Müllerian inhibiting substance Nature 345 167–170
Behringer RR, Finegold MJ and Cate RL (1994) Müllerian-inhibiting
substance function during mammalian sexual development Cell 79
415–425
Brown JB (1978) Pituitary control of ovarian function: concepts derived
from gonadotrophin therapy Australian and New Zealand Journal of
Obstetrics and Gynaecology 18 46–54
Cate RL, Mattaliano RJ, Hession C et al. (1986) Isolation of the bovine and
human genes for Müllerian inhibiting substance and expression of the
human gene in animal cells Cell 45 685–698
Chin TW, Parry RL and Donahoe PK (1991) Human Müllerian inhibiting
substance inhibits tumor growth in vitro and in vivo. Cancer Research
51 2101–2106
Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM and Donahoe PK (2001)
Müllerian inhibiting substance signaling uses a bone morphogenetic
protein (BMP)-like pathway mediated by ALK2 and induces SMAD6
expression Molecular Endocrinology 15 946–959 
de Vet A, Laven JS, de Jong FH, Themmen AP and Fauser BC (2002) Anti-
Müllerian hormone serum levels: a putative marker for ovarian aging
Fertility and Sterility 77 357–362
Dewulf N, Verschueren K, Lonnoy O, Moren A, Grimsby S, Vande Spiegle
K, Miyazono K, Huylebroeck D and Ten Dijke P (1995) Distinct spatial
and temporal expression patterns of two type I receptors for bone
morphogenetic proteins during mouse embryogenesis Endocrinology
136 2652–2663
di Clemente N, Goxe B, Rémy JJ, Cate RL, Josso N, Vigier B and Salesse R
(1994a) Inhibitory effect of AMH upon the expression of aromatase
activity and LH receptors by cultured granulosa cells of rat and porcine
immature ovaries Endocrine 2 553–558
di Clemente N, Wilson C, Faure E et al. (1994b) Cloning, expression, and
alternative splicing of the receptor for anti-Müllerian hormone
Molecular Endocrinology 8 1006–1020 
Dissen GA, Romero C, Hirshfield AN and Ojeda SR (2001) Nerve growth
factor is required for early follicular development in the mammalian
ovary Endocrinology 142 2078–2086
Dong J, Albertini DF, Nishimori K, Kumar TR, Lu N and Matzuk MM (1996)
Growth differentiation factor-9 is required during early ovarian
folliculogenesis Nature 383 531–535
Durlinger AL (2000) Ovarian Follicle Growth and Development: Role of
Anti-Müllerian Hormone PhD Thesis, Erasmus University, Rotterdam
*Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed
JA and Themmen AP (1999) Control of primordial follicle recruitment 
by anti-Müllerian hormone in the mouse ovary Endocrinology 140
5789–5796
*Durlinger AL, Gruijters MJ, Kramer P et al. (2001) Anti-Müllerian
hormone attenuates the effects of FSH on follicle development in the
mouse ovary Endocrinology 142 4891–4899 
*Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal
MW, Uilenbroek JT, Grootegoed JA and Themmen AP (2002) Anti-
Müllerian hormone inhibits initiation of primordial follicle growth in the
mouse ovary Endocrinology 143 1076–1084
Elvin JA, Clark AT, Wang P, Wolfman NM and Matzuk MM (1999a)
Paracrine actions of growth differentiation factor-9 in the mammalian
ovary Molecular Endocrinology 13 1035–1048
Elvin JA, Yan C, Wang P, Nishimori K and Matzuk MM (1999b) Molecular
characterization of the follicle defects in the growth differentiation factor
9-deficient ovary Molecular Endocrinology 13 1018–1034
Fuller AF, Jr, Krane IM, Budzik GP and Donahoe PK (1985) Müllerian
inhibiting substance reduction of colony growth of human gynecologic
cancers in a stem cell assay Gynecologic Oncology 22 135–148
Gouedard L, Chen YG, Thevenet L, Racine C, Borie S, Lamarre I, Josso N,
Massagué J and di Clemente N (2000) Engagement of bone morpho-
genetic protein type IB receptor and Smad1 signaling by anti-Müllerian
hormone and its type II receptor Journal of Biological Chemistry 275 27
973–27 978
Gustafson ML, Lee MM, Scully RE et al. (1992) Müllerian inhibiting
substance as a marker for ovarian sex-cord tumor New England Journal
of Medicine 326 466–471
Ha TU, Segev DL, Barbie D et al. (2000) Müllerian inhibiting substance
inhibits ovarian cell growth through an Rb-independent mechanism
Journal of Biological Chemistry 275 37 101–37 109
Halpin DM and Charlton HM (1988) Effects of short-term injection of
gonadotrophins on ovarian follicle development in hypogonadal (hpg)
mice Journal of Reproduction and Fertility 82 393–400
Hayashi M, McGee EA, Min G, Klein C, Rose UM, van Duin M and Hsueh
AJ (1999) Recombinant growth differentiation factor-9 (GDF-9)
enhances growth and differentiation of cultured early ovarian follicles
Endocrinology 140 1236–1244
Hirobe S, He WW, Lee MM and Donahoe PK (1992) Müllerian inhibiting
substance messenger ribonucleic acid expression in granulosa and
Sertoli cells coincides with their mitotic activity Endocrinology 131
854–862
Hirobe S, He WW, Gustafson ML, MacLaughlin DT and Donahoe PK
(1994) Müllerian inhibiting substance gene expression in the cycling rat
ovary correlates with recruited or Graafian follicle selection Biology and
Reproduction 50 1238–1243
Hirshfield AN and De Paolo LV (1981) Effect of suppression of the surge of
follicle-stimulating hormone with porcine follicular fluid on follicular
development in the rat Journal of Endocrinology 88 67–71
Imbeaud S, Belville C, Messika-Zeitoun L, Rey R, di Clemente N, Josso N
and Picard JY (1996) A 27 base-pair deletion of the anti-Müllerian
hormone type II receptor gene is the most common cause of the
persistent Müllerian duct syndrome Human Molecular Genetics 5
1269–1277
Ingraham HA, Hirokawa Y, Roberts LM, Mellon SH, McGee E, Nachtigal
MW and Visser JA (2000) Autocrine and paracrine Müllerian inhibiting
substance hormone signaling in reproduction Recent Progress in
Hormone Research 55 53–67; discussion 67–68
Josso N, Picard JY, Imbeaud S, di Clemente N and Rey R (1997) Clinical
aspects and molecular genetics of the persistent Müllerian duct
syndrome Clinical Endocrinology 47 137–144
Jost A (1947) Reserches sur la differenciation sexuelle de l’embryon de lapin
Archives d’Anatomie Microscopique et de Morphologie Expérimentale
36 271–315
608 A. L. L. Durlinger et al.
Kim JH, Seibel MM, MacLaughlin DT, Donahoe PK, Ransil BJ, Hametz PA
and Richards CJ (1992) The inhibitory effects of Müllerian-inhibiting
substance on epidermal growth factor induced proliferation and
progesterone production of human granulosa-luteal cells Journal of
Clinical Endocrinology and Metabolism 75 911–917
Kumar TR, Wang Y, Lu N and Matzuk MM (1997) Follicle stimulating
hormone is required for ovarian follicle maturation but not male fertility
Nature Genetics 15 201–204
Lane AH, Lee MM, Fuller AF, Jr, Kehas DJ, Donahoe PK and MacLaughlin DT
(1999) Diagnostic utility of Müllerian inhibiting substance deter-
mination in patients with primary and recurrent granulosa cell tumors
Gynecologic Oncology 73 51–55
Lee MM, Donahoe PK, Hasegawa T et al. (1996) Müllerian inhibiting
substance in humans: normal levels from infancy to adulthood Journal of
Clinical Endocrinology and Metabolism 81 571–576
Long WQ, Ranchin V, Pautier P et al. (2000) Detection of minimal levels of
serum anti-Müllerian hormone during follow-up of patients with ovarian
granulosa cell tumor by means of a highly sensitive enzyme-linked
immunosorbent assay Journal of Clinical Endocrinology and Metabolism
85 540–544
*McGee EA and Hsueh AJ (2000) Initial and cyclic recruitment of ovarian
follicles Endocrine Reviews 21 200–214
McGee EA, Perlas E, LaPolt PS, Tsafriri A and Hsueh AJ (1997) Follicle-
stimulating hormone enhances the development of preantral follicles in
juvenile rats Biology of Reproduction 57 990–998
McGee EA, Smith R, Spears N, Nachtigal MW, Ingraham H and Hsueh AJ
(2001) Müllerian inhibitory substance induces growth of rat preantral
ovarian follicles Biology of Reproduction 64 293–298
Masiakos PT, MacLaughlin DT, Maheswaran S et al. (1999) Human ovarian
cancer, cell lines, and primary ascites cells express the human Müllerian
inhibiting substance (MIS) type II receptor, bind, and are responsive to
MIS Clinical Cancer Research 5 3488–3499
Massagué J (1990) The transforming growth factor-b family Annual Review
of Cell Biology 6 597–641
Massagué J and Chen YG (2000) Controlling TGF-b signaling Genes and
Development 14 627–644
Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL and
Behringer RR (1996) Genetic analysis of the Müllerian-inhibiting
substance signal transduction pathway in mammalian sexual
differentiation Genes and Development 10 2577–2587
Munsterberg A and Lovell-Badge R (1991) Expression of the mouse anti-
Müllerian hormone gene suggests a role in both male and female sexual
differentiation Development 113 613–624
Nakao A, Imamura T, Souchelnytskyi S et al. (1997) TGF-b receptor-
mediated signalling through Smad2, Smad3 and Smad4 EMBO Journal
16 5353–5362
Nilsson E, Parrott JA and Skinner MK (2001) Basic fibroblast growth factor
induces primordial follicle development and initiates folliculogenesis
Molecular and Cellular Endocrinology 175 123–130
Parrott JA and Skinner MK (1997) Direct actions of kit-ligand on theca cell
growth and differentiation during follicle development Endocrinology
138 3819–3827
Parrott JA and Skinner MK (1999) Kit-ligand/stem cell factor induces
primordial follicle development and initiates folliculogenesis
Endocrinology 140 4262–4271
Parry RL, Chin TW, Epstein J, Hudson PL, Powell DM and Donahoe PK
(1992) Recombinant human Müllerian inhibiting substance inhibits
human ocular melanoma cell lines in vitro and in vivo. Cancer Research
52 1182–1186
Perez GI, Robles R, Knudson CM, Flaws JA, Korsmeyer SJ and Tilly JL
(1999) Prolongation of ovarian lifespan into advanced chronological
age by Bax-deficiency Nature Genetics 21 200–203
Rajpert-De Meyts E, Jorgensen N, Graem N, Muller J, Cate RL and
Skakkebaek NE (1999) Expression of anti-Müllerian hormone during
normal and pathological gonadal development: association with
differentiation of Sertoli and granulosa cells Journal of Clinical
Endocrinology and Metabolism 84 3836–3844
Rey RA, Lhommé C, Marcillac I, Lahlou N, Duvillard P, Josso N and Bidart JM
(1996) Anti-Müllerian hormone as a serum marker of granulosa cell
tumors of the ovary: comparative study with serum alpha-inhibin and
estradiol American Journal of Obstetrics and Gynecology 174 958–965
Rey R, Sabourin JC, Venara M, Long WQ, Jaubert F, Zeller WP, Duvillard P,
Chemes H and Bidart JM (2000) Anti-Müllerian hormone is a specific
marker of Sertoli- and granulosa-cell origin in gonadal tumors Human
Pathology 31 1202–1208
Scheffer GJ, Broekmans FJ, Dorland M, Habbema JD, Looman CW and te
Velde ER (1999) Antral follicle counts by transvaginal ultrasonography
are related to age in women with proven natural fertility Fertility and
Sterility 72 845–851
Scully RE (1995) Pathology of ovarian cancer precursors Journal of Cellular
Biochemistry Supplement 23 208–218
Seifer DB, MacLaughlin DT, Christian BP, Feng B and Shelden RM (2002)
Early follicular serum Müllerian-inhibiting substance levels are
associated with ovarian response during assisted reproductive
technology cycles Fertility and Sterility 77 468–471
Silverman LA and Gitelman SE (1996) Immunoreactive inhibin, Müllerian
inhibitory substance, and activin as biochemical markers for juvenile
granulosa cell tumors Journal of Pediatrics 129 918–921
Stephen AE, Masiakos PT, Segev DL, Vacanti JP, Donahoe PK and
MacLaughlin DT (2001) Tissue-engineered cells producing complex
recombinant proteins inhibit ovarian cancer in vivo. Proceedings
National Academy of Sciences USA 98 3214–3219
Takahashi M, Koide SS and Donahoe PK (1986) Müllerian inhibiting substance
as oocyte meiosis inhibitor Molecular and Cellular Endocrinology 47
225–234
Taketo T, Saeed J, Manganaro T, Takahashi M and Donahoe PK (1993)
Müllerian inhibiting substance production associated with loss of
oocytes and testicular differentiation in the transplanted mouse XX
gonadal primordium Biology of Reproduction 49 13–23
*Teixeira J, Saeed J, Manganaro T, Takahashi M and Donahoe PK (2001)
Müllerian inhibiting substance: an instructive development hormone
with diagnostic and possible therapeutic applications Endocrine Reviews
22 657–674
Tsafriri A, Picard JY and Josso N Immunopurified anti-Müllerian hormone
does not inhibit spontaneous resumption of meiosis in vitro of rat
oocytes Biology of Reproduction 38 481–485
Ueno S, Kuroda T, Maclaughlin DT, Ragin RC, Manganaro TF and Donahoe
PK (1989) Müllerian inhibiting substance in the adult rat ovary during
various stages of the estrous cycle Endocrinology 125 1060–1066
van Cappellen WA, Meijs-Roelofs HM, Kramer P and Van den Dungen HM
(1989) Ovarian follicle dynamics in immature rats treated with a
luteinizing hormone-releasing hormone antagonist (Org. 30276)
Biology of Reproduction 40 1247–1256
van Cappellen WA, Osman P and Meijs-Roelofs HM (1993) Model of antral
follicle dynamics during the 5-day cycle in rats based on measurement
of antral follicle inflow Journal of Reproduction and Fertility 99 57–63
Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP and Ingraham
HA (2001) The serine/threonine transmembrane receptor ALK2 mediates
Müllerian inhibiting substance signaling Molecular Endocrinology 15
936–945
Vitt UA, McGee EA, Hayashi M and Hsueh AJ (2000) In vivo treatment with
GDF-9 stimulates primordial and primary follicle progression and theca
cell marker CYP17 in ovaries of immature rats Endocrinology 141
3814–3820
Yi SE, LaPolt PS, Yoon BS, Chen JY, Lu JK and Lyons KM (2001) The type I
BMP receptor BmprIB is essential for female reproductive function
Proceedings National Academy of Sciences USA 98 7994–7999
AMH action in the ovary 609
